

Supplemental Material

De Novo ANCA-associated Vasculitis with Glomerulonephritis in COVID-19 and the Role of Immunosuppression

Authors: Nupur N Uppal¹, Nina Kello², Hitesh H Shah¹, Yuriy Khanin¹, Ivan Ramirez De Oleo², Edward Epstein^{3,4}, Purva D Sharma¹, Christopher P Larsen⁶, Vanesa Bijol⁵, Kenar D Jhaveri¹

Supplemental References (S1-S14)

- S1. Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, Wang C, Liu L, Liu Y, Liu Y, Wang G, Yuan Z, Ren L, Wu Y, Chen Y: Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *MedRxiv* Jan 2020.
- S2. Staico MF, Zaffanello M, Di Pietro G, Fanos V, Marcialis MA. The kidney in COVID-19: protagonist or figurant? [published online ahead of print, 2020 May 20]. *Panminerva Med.* 2020;10.23736/S0031-0808.20.03965-8. doi:10.23736/S0031-0808.20.03965-8
- S3. Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. *Lancet.* May 2020. doi:10.1016/S0140-6736(20)31129-6
- S4. Menter T, Haslbauer JD, Nienhold R, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. *Histopathology.* May 2020:his.14134. doi:10.1111/his.14134
- S5. Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. *Infect Dis Clin North Am.* 2001;15(3):813-832. doi:10.1016/s0891-5520(05)70174-4
- S6. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. *J Clin Invest.* 2002;110(7):955-963. doi:10.1172/JCI15918
- S7. Fousert E, Toes R, Desai J. Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses. *Cells.* 2020;9(4):915. doi:10.3390/cells9040915
- S8. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *J Exp Med.* 2020;217(6). doi:10.1084/jem.20200652
- S9. Guilpain P, Le Bihan C, Foulongne V, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia [published online ahead of print, 2020 Apr 20]. *Ann Rheum Dis.* 2020;annrheumdis-2020-217549. doi:10.1136/annrheumdis-2020-217549

- S10. Fallet B, Kyburz D, Walker UA. Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B-cells due to treatment with rituximab [published online ahead of print, 2020 May 26]. *Arthritis Rheumatol.* 2020;10.1002/art.41380. doi:10.1002/art.41380
- S11 Novi G, Mikulska M, Briano F, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? [published online ahead of print, 2020 Apr 15]. *Mult Scler Relat Disord.* 2020;42:102120. doi:10.1016/j.msard.2020.102120
- S12. Zhang L, Zhang F, Yu W, et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. *J Med Virol.* 2006;78(1):1-8. doi:10.1002/jmv.20499
- S13. Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover [published online ahead of print, 2020 Apr 22]. *Pediatr Allergy Immunol.* 2020;10.1111/pai.13263. doi:10.1111/pai.13263S
- S14. Anders HJ, Bruchfeld A, Fernandez Juarez GM, et al. Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic [published online ahead of print, 2020 May 23]. *Nephrol Dial Transplant.* 2020;gfaa112. doi:10.1093/ndt/gfaa112